24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ABIRALIEVA 500 MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ABIRALIEVA 500 MG |
|---|---|
| Composition | Abiraterone Acetate Tablets IP 500mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (60 Tab) |
| Country of Origin | India |
ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500 mg) is a prescription anticancer medicine containing Abiraterone Acetate 500 mg, a targeted hormonal therapy used primarily for the treatment of prostate cancer. It is commonly prescribed for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) as part of a comprehensive oncology treatment plan.
Abiraterone Acetate belongs to a class of medicines known as androgen biosynthesis inhibitors. Prostate cancer cells often depend on male hormones called androgens, particularly testosterone, to grow and multiply. ABIRALIEVA 500 MG works by blocking an enzyme called CYP17 (17α-hydroxylase/C17,20-lyase), which plays a crucial role in the production of androgens in the testes, adrenal glands, and tumor tissues.
By significantly reducing androgen levels throughout the body, Abiraterone helps slow the growth and spread of prostate cancer cells. This targeted mechanism has made it one of the most important advances in the treatment of advanced prostate cancer.
Unlike conventional chemotherapy, Abiraterone specifically targets hormone production pathways associated with prostate cancer progression. It is frequently prescribed alongside corticosteroids such as prednisone or prednisolone to help manage certain treatment-related effects and optimize therapeutic outcomes.
ABIRALIEVA 500 MG is commonly prescribed for:
The medicine has become a cornerstone of modern prostate cancer treatment due to its ability to improve disease control and support long-term management strategies.
Manufactured under stringent pharmaceutical quality standards, ABIRALIEVA 500 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Abiraterone therapy typically undergo regular monitoring, including liver function tests, blood pressure assessments, potassium level evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven clinical efficacy and targeted hormonal action, ABIRALIEVA 500 MG remains an important treatment option in advanced prostate cancer care worldwide.
ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500 mg) is primarily used for the treatment and management of advanced prostate cancer.
The medicine is widely prescribed for patients whose prostate cancer continues to progress despite androgen deprivation therapy.
Abiraterone may be used in combination treatment plans for newly diagnosed metastatic hormone-sensitive disease.
The medicine helps manage advanced stages of prostate cancer.
Doctors may prescribe Abiraterone when prostate cancer returns after previous treatment.
The medicine forms part of targeted hormonal treatment strategies.
Abiraterone helps slow disease progression and maintain treatment response.
The medicine supports individualized cancer treatment approaches.
Abiraterone Acetate belongs to a class of medicines known as Androgen Biosynthesis Inhibitors.
ABIRALIEVA works by:
This targeted hormonal mechanism helps control prostate cancer and improve treatment outcomes.
Like all medicines, ABIRALIEVA 500 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are commonly reported during treatment.
Some patients may experience elevated blood pressure levels.
Swelling in the feet, ankles, or legs may occur.
Musculoskeletal discomfort may develop during therapy.
The medicine may affect potassium balance in the body.
Some patients may experience episodes of warmth and sweating.
Headaches may occasionally occur during treatment.
Nausea, indigestion, or abdominal discomfort may develop.
Regular monitoring may be required due to possible liver-related effects.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of ABIRALIEVA 500 MG (Abiraterone Acetate Tablets IP 500 mg) should always be determined by a qualified oncologist.
The severity and progression of prostate cancer influence treatment planning.
Doctors may adjust therapy according to effectiveness and patient tolerance.
Liver health plays an important role in dosage considerations.
Other medicines may influence treatment decisions.
Individual patient factors contribute to dosage recommendations.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant women should avoid exposure to crushed or damaged tablets. The medicine should only be used according to medical recommendations.
It is primarily used for the treatment of advanced and metastatic prostate cancer.
Abiraterone Acetate is a hormonal anticancer medicine that reduces androgen production to help control prostate cancer growth.
No. It is a hormonal targeted therapy and works differently from traditional chemotherapy.
Corticosteroids may be prescribed to help manage certain treatment-related effects and improve overall therapy outcomes.
Yes. Liver function changes may occur, which is why regular monitoring is important.
Yes. It works by reducing androgen production, including testosterone.
Yes. Blood tests, liver assessments, potassium monitoring, and blood pressure checks are important throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and prostate cancer treatment.